BrainsWay Expands Its Reach in East Asia
BURLINGTON, Mass., and JERUSALEM, Israel — BrainsWay Ltd. (NASDAQ: BWAY), a recognized leader in innovative neurostimulation treatments, has announced a remarkable expansion of its Deep Transcranial Magnetic Stimulation (Deep TMS™) platform. Recently, the company successfully placed 15 additional systems in key regions of East Asia, specifically in Taiwan and South Korea, amplifying its impact on mental health treatment.
Significant Growth in Mental Health Solutions
The placement of these new Deep TMS systems reflects the overwhelming demand and commercial success BrainsWay has encountered while penetrating this strategically significant area. Both Taiwan and South Korea are integral to BrainsWay's international growth vision. The Chief Executive Officer of BrainsWay, Hadar Levy, stated that these recent orders represent a growing interest in advanced mental health solutions across the region. He emphasized the commitment of the BrainsWay team and its international distribution partners to enhance access to Deep TMS, ensuring that more patients and healthcare professionals can benefit from this leading-edge technology.
Understanding Deep TMS Technology
Deep TMS® is a noninvasive technique that uses magnetic fields to stimulate nerve cells in the brain, providing effective treatment for various mental health disorders. Unlike traditional methods that require invasive procedures, Deep TMS aims to transform the lives of individuals suffering from conditions such as major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The technology is backed by extensive clinical studies that showcase its efficacy, making it a sought-after solution in the realm of mental health.
Innovative Approaches to Mental Health Care
BrainsWay is proud to be the first TMS company to receive FDA clearance for multiple indications, showcasing its dedication to cutting-edge science and patient care. The latest placement of Deep TMS systems is a testament to the company's commitment to evolving mental health care. The firm continues to conduct additional clinical trials exploring the benefits of Deep TMS in various psychiatric and neurological disorders, thereby broadening the scope and understanding of neurostimulation techniques.
Global Expansion and Future Plans
With a history dating back to 2003, BrainsWay has consistently worked towards increasing awareness and broad access to its innovative technology. Offices in Burlington, MA, and Jerusalem, Israel, play a pivotal role in the company's operational framework, allowing it to engage and connect with diverse markets. As the demand for mental health solutions rises globally, BrainsWay's expansion signifies its forward momentum and ambitious vision for the future.
Commitment to Clinical Excellence
Through its commitment to superior science and a robust body of clinical evidence, BrainsWay is not just expanding its geographical footprint; it is also enhancing the quality of care available to patients. The combination of Bridging science with practical applications in healthcare underscores BrainsWay's mission to improve patient outcomes and transform lives under the principles of compassion and innovation.
Company Contacts
For more information or inquiries regarding BrainsWay, interested parties can reach out to Ido Marom, Chief Financial Officer at BrainsWay, or Brian Ritchie from LifeSci Advisors LLC. Their commitment to promoting BrainsWay's innovative technology is essential as they navigate the evolving landscape of mental health care.
Frequently Asked Questions
What is BrainsWay's focus in East Asia?
BrainsWay aims to enhance mental health treatment options in East Asia with its Deep TMS systems, addressing the growing demand for effective solutions.
How effective is Deep TMS in treating mental health conditions?
Deep TMS has been proven effective in treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction through extensive clinical studies.
What does BrainsWay's expansion mean for mental health care?
The expansion signifies increased access to high-quality mental health treatment options for communities in Taiwan and South Korea, improving overall patient care.
What regulatory approvals does Deep TMS have?
BrainsWay's Deep TMS technology has received FDA clearance for multiple indications, showcasing its clinically validated efficacy.
Who can I contact for more information about BrainsWay?
For insights about the company and its offerings, you can contact Ido Marom, Chief Financial Officer, or Brian Ritchie from LifeSci Advisors LLC.
